Serpi Michaela, Krylov Ivan S, Zakharova Valeria M, McKenna Charles E
University of Southern California, Los Angeles, USA.
Curr Protoc Nucleic Acid Chem. 2010 Dec;Chapter 15:Unit15.4. doi: 10.1002/0471142700.nc1504s43.
Cyclic nucleoside phosphonates connected through a P-O-C linkage to a promoiety represent a class of prodrugs designed to overcome the low oral bioavailability of parent antiviral acyclic nucleoside phosphonates. In our prodrug approach, a nontoxic promoiety, such as an amino acid or dipeptide, is conjugated to the cyclic form of the parent drug by esterification of the phosphonic acid moiety with an alcoholic amino acid side chain (Ser, Tyr, and Thr) or a glycol linker. For the biological evaluation and investigation of the pharmacokinetic profiles of these modified nucleoside phosphonates, a reliable synthetic procedure that allows preparation of sufficient amount of potential prodrugs is needed. This unit provides a procedure for synthesizing peptidomimetic conjugates of two broad-spectrum antiviral acyclic nucleoside phosphonates: (S)-HPMPC and (S)-HPMPA. Two alternate strategies allowing synthesizing selected amino acid, dipeptide, or ethylene glycol-linked amino acid prodrugs of (S)-HPMPC and (S)-HPMPA in solution and using a solid-phase approach are presented.
通过磷氧碳(P-O-C)键连接到一个前体部分的环状核苷膦酸酯代表一类前药,其设计目的是克服母体抗病毒无环核苷膦酸酯口服生物利用度低的问题。在我们的前药方法中,一个无毒的前体部分,如氨基酸或二肽,通过用含醇的氨基酸侧链(丝氨酸、酪氨酸和苏氨酸)或二醇连接体将膦酸部分酯化,与母体药物的环状形式共轭。为了对这些修饰的核苷膦酸酯进行生物学评价和药代动力学概况研究,需要一种可靠的合成方法,以制备足够量的潜在前药。本单元提供了一种合成两种广谱抗病毒无环核苷膦酸酯:(S)-HPMPC和(S)-HPMPA的拟肽共轭物的方法。介绍了两种允许在溶液中并使用固相方法合成(S)-HPMPC和(S)-HPMPA的选定氨基酸、二肽或乙二醇连接的氨基酸前药的替代策略。